Regulus Therapeutics Inc (RGLS) 6.20 $RGLS
Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
PR Newswire - Wed Jul 30, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended June 30, 2014 on Wednesday, August 6, 2014, after the U.S. financial markets close.
Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
PR Newswire - Mon Jul 21, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"
, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.
Commit To Purchase Regulus Therapeutics At $5, Earn 16.2% Annualized Using Options
StockOptionsChannel.com - Thu Jul 10, 10:54AM CDT
Investors eyeing a purchase of Regulus Therapeutics Inc shares, but tentative about paying the going market price of $6.85/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Regulus Announces Patent Grant from U.S. Patent Office in Sarnow Patent Estate on microRNA Therapeutics for the Treatment of HCV
PR Newswire - Wed Jun 25, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark Office ("USPTO" has granted a patent in the company's exclusively licensed 'Sarnow' patent estate, for claims related to targeting microRNA-122 ("miR-122" for the treatment of HCV in combination with other anti-viral therapies. The Sarnow patent estate, owned by Stanford University and exclusively licensed to Regulus, has produced patents in Europe, Japan and the United States covering the use of a broad class of anti-miR inhibitors of miR-122 for the treatment of HCV as monotherapy or in combination with other anti-viral therapies. Regulus' lead asset, RG-101, a GalNAc-conjugated anti-miR that targets miR-122, is being evaluated in a Phase I clinical study for the treatment of HCV. Regulus expects to demonstrate human proof-of-concept results from Part IV of the Phase I study by the end of 2014. If favorable, these results may positively advance Regulus' microRNA technology platform and provide clinical support for its unique approach to treating disease.
Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer
PR Newswire - Mon Jun 16, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus' microRNA clinical portfolio and will serve as a key member of its executive leadership team.
Ironwood Pharmaceuticals names Dr Douglas Williams to board
M2 - Thu Jun 05, 5:17AM CDT
Medicine company Ironwood Pharmaceuticals (NasdaqGS:IRWD) revealed on Wednesday the appointment of Douglas Williams PhD, to its board of directors.
Regulus and Alport Syndrome Foundation Raise Awareness of Life-Threatening, Genetic Kidney Disease
PR Newswire - Tue Mar 25, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and the Alport Syndrome Foundation ("ASF" , a non-profit corporation, announced today they are working together to raise awareness of Alport Syndrome, a life-threatening genetic kidney disease driven by genetic mutations with no approved therapy.
Global miRNA Market Outlook to 2018 Report Provides an In-Depth Analysis of the Various Aspects of R&D within the miRNA Industry
M2 - Tue Mar 18, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jfvz6/global_mirna) has announced the addition of the "Global miRNA Market Outlook to 2018" report to their offering. The recent discovery of miRNA and its wide applicability have sparked off a lot of interest among researchers as well as commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of miRNA in diverse fields such as Cancer, Asthma, Heart disorders, Diabetes, Hepatitis etc. The market has been divided into three sections i.e., The Americas, Europe and Asia Pacific. These regions have then been analyzed to draw patterns in terms of research areas and applicability. A brief look at the market suggests that cancer is the most researched topic and regions such as United States, United Kingdom, France, Israel and China are the major players interested in evaluating the role played by miRNA. Most of the current research is focused on utilizing miRNA for diagnostic purposes such as expression profiling, response evaluation and setting potential biomarkers in diseases. Another applications are in the field of therapeutics where miRNA mimics and inhibitors are being applied to control gene translation and consequently its expression. After an exhaustive study of the industry, the authors have laid out the primary market players. These players are working over a vast variety of products such as miRNA extraction and purification kits, and miRNA mimics and inhibitors. There are other players who are solely providing miRNA associated diagnostic services and assessing their therapeutic potential. Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the miRNA market is bound to witness rampant diversification and growth in the coming years. Companies Mentioned: - Agilent Technologies Inc. - GeneCopoeia - InteRNA Technologies B.V. - Life Technologies Corporation - miRagen Therapeutics - Mirna Therapeutics, Inc. - Qiagen - Regulus Therapeutics - Rosetta Genomics, Ltd. - Santaris Pharma A/S - Sigma-Aldrich Corporation - System Biosciences - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/8j...obal_mirna About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Focus on Regulus' Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 6:00PM CDT
Regulus is working hard to develop its pipeline.
Regulus Commences Dosing RG-101 in Healthy Volunteers in Phase I Study
PR Newswire - Wed Mar 05, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122" in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study is to evaluate safety and tolerability of RG-101 and the secondary objectives are to evaluate pharmacokinetics, viral load reduction and any impact an oral direct-acting antiviral may have on the pharmacokinetics of RG-101.
Regulus Provides Strategic Update and Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights
PR Newswire - Thu Feb 27, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights.
Regulus to Present at Cowen and Company 34th Annual Healthcare Conference
PR Newswire - Wed Feb 26, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:40 am EST. The conference is being held at the Boston Marriott Copley Place.
UMB Health IT Start-up Advanced Metrics Caps Quick Entrance into Commercialization with Move to University of Maryland BioPark
PR Newswire - Wed Feb 26, 7:30AM CST
The University of Maryland (UM) BioPark and UM Ventures announced today that Advanced Metrics, a successful early-stage UM, Baltimore (UMB) startup has moved from offices on the University's campus to the BioPark. Advanced Metrics is leveraging software development and data expertise to provide solutions for the healthcare industry. It has moved quickly into commercialization since establishment only a year ago. Two employees will develop the company's technologies at the BioPark. The company also has additional staff in Mountville, Pennsylvania.
Pipeline Progress at Regulus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:20PM CST
RG-012 will be moved into clinical development next year.
Regulus Announces Timing for Fourth Quarter and Year-End 2013 Financial Results Webcast and Conference Call
PR Newswire - Thu Feb 20, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close.
Regulus Advances Orphan Disease Portfolio with Nomination of RG-012 as Clinical Development Candidate for the Treatment of Alport Syndrome
PR Newswire - Wed Feb 19, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical development, RG-012, an anti-miR targeting microRNA-21 ("miR-21" for the treatment of Alport Syndrome, a life-threatening, genetic kidney disease with no approved therapy.
Crude Oil Refining Industry in Middle East and Africa: Market Data and Business Intelligence of All Operational and New Build Refineries
PR Newswire - Thu Feb 13, 1:14PM CST
Reportbuyer.com just published a new market research report:
Regulus Appoints Head of Regulus microMarkers(TM) R&D Division
PR Newswire - Thu Feb 13, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Martin Beaulieu, Ph.D. as the head of Regulus microMarkers(TM), a research and development division of Regulus designed to support the expansion of its innovative biomarkers platform aimed at identifying microRNAs as biomarkers for disease. Regulus microMarkers(TM) utilizes a clinically-validated, highly reproducible, proprietary technology platform to extract, profile, and analyze microRNAs as potential biomarkers for disease and Regulus controls key intellectual property and know-how related to the division.
Annai Systems Names David Szekeres to its Board of Directors
PRWeb - Tue Feb 11, 5:45AM CST
Annai Systems Inc., a genomic data management solution provider, today announced that David Szekeres has joined the company's Board of Directors.
Regulus Renews Strategic Alliance with Sanofi to Focus on Orphan Disease and Oncology Targets and Receives Additional $10 Million Equity Investment
PR Newswire - Wed Feb 05, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced today that it has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regulus will lead development of its fibrosis program targeting microRNA-21 ("miR-21" for the treatment of Alport Syndrome, an orphan, life-threatening genetic kidney disease with no approved therapy, and for its microRNA-21 ("miR-21" program in oncology. Sanofi has retained its interest in these microRNA-21 programs and has gained rights to Regulus' preclinical program targeting microRNA-221/microRNA-222 ("miR-221/222" . Regulus is responsible for advancing the clinical candidates in these programs to proof-of-concept. Sanofi shall have the exclusive option, exercisable after proof-of-concept, to take over further development and commercialization of each microRNA therapeutic program. At this stage, Regulus will have the option to co-promote any microRNA therapeutic product in the United States.
Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call
PR Newswire - Wed Jul 30, 3:05PM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended June 30, 2014 on Wednesday, August 6, 2014, after the U.S. financial markets close.
Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome
PR Newswire - Mon Jul 21, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"
, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. Commit To Purchase Regulus Therapeutics At $5, Earn 16.2% Annualized Using Options
StockOptionsChannel.com - Thu Jul 10, 10:54AM CDT
Investors eyeing a purchase of Regulus Therapeutics Inc shares, but tentative about paying the going market price of $6.85/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
Regulus Announces Patent Grant from U.S. Patent Office in Sarnow Patent Estate on microRNA Therapeutics for the Treatment of HCV
PR Newswire - Wed Jun 25, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that the U.S. Patent and Trademark Office ("USPTO"
has granted a patent in the company's exclusively licensed 'Sarnow' patent estate, for claims related to targeting microRNA-122 ("miR-122" for the treatment of HCV in combination with other anti-viral therapies. The Sarnow patent estate, owned by Stanford University and exclusively licensed to Regulus, has produced patents in Europe, Japan and the United States covering the use of a broad class of anti-miR inhibitors of miR-122 for the treatment of HCV as monotherapy or in combination with other anti-viral therapies. Regulus' lead asset, RG-101, a GalNAc-conjugated anti-miR that targets miR-122, is being evaluated in a Phase I clinical study for the treatment of HCV. Regulus expects to demonstrate human proof-of-concept results from Part IV of the Phase I study by the end of 2014. If favorable, these results may positively advance Regulus' microRNA technology platform and provide clinical support for its unique approach to treating disease. Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer
PR Newswire - Mon Jun 16, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Paul C. Grint, M.D. to its executive management team as Chief Medical Officer. In his new role, Dr. Grint will be responsible for leading and expanding Regulus' microRNA clinical portfolio and will serve as a key member of its executive leadership team.
Ironwood Pharmaceuticals names Dr Douglas Williams to board
M2 - Thu Jun 05, 5:17AM CDT
Medicine company Ironwood Pharmaceuticals (NasdaqGS:IRWD) revealed on Wednesday the appointment of Douglas Williams PhD, to its board of directors.
Regulus and Alport Syndrome Foundation Raise Awareness of Life-Threatening, Genetic Kidney Disease
PR Newswire - Tue Mar 25, 7:00AM CDT
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and the Alport Syndrome Foundation ("ASF"
, a non-profit corporation, announced today they are working together to raise awareness of Alport Syndrome, a life-threatening genetic kidney disease driven by genetic mutations with no approved therapy. Global miRNA Market Outlook to 2018 Report Provides an In-Depth Analysis of the Various Aspects of R&D within the miRNA Industry
M2 - Tue Mar 18, 10:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8jfvz6/global_mirna) has announced the addition of the "Global miRNA Market Outlook to 2018" report to their offering. The recent discovery of miRNA and its wide applicability have sparked off a lot of interest among researchers as well as commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of miRNA in diverse fields such as Cancer, Asthma, Heart disorders, Diabetes, Hepatitis etc. The market has been divided into three sections i.e., The Americas, Europe and Asia Pacific. These regions have then been analyzed to draw patterns in terms of research areas and applicability. A brief look at the market suggests that cancer is the most researched topic and regions such as United States, United Kingdom, France, Israel and China are the major players interested in evaluating the role played by miRNA. Most of the current research is focused on utilizing miRNA for diagnostic purposes such as expression profiling, response evaluation and setting potential biomarkers in diseases. Another applications are in the field of therapeutics where miRNA mimics and inhibitors are being applied to control gene translation and consequently its expression. After an exhaustive study of the industry, the authors have laid out the primary market players. These players are working over a vast variety of products such as miRNA extraction and purification kits, and miRNA mimics and inhibitors. There are other players who are solely providing miRNA associated diagnostic services and assessing their therapeutic potential. Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the miRNA market is bound to witness rampant diversification and growth in the coming years. Companies Mentioned: - Agilent Technologies Inc. - GeneCopoeia - InteRNA Technologies B.V. - Life Technologies Corporation - miRagen Therapeutics - Mirna Therapeutics, Inc. - Qiagen - Regulus Therapeutics - Rosetta Genomics, Ltd. - Santaris Pharma A/S - Sigma-Aldrich Corporation - System Biosciences - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/8j...obal_mirna About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Focus on Regulus' Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 6:00PM CDT
Regulus is working hard to develop its pipeline.
Regulus Commences Dosing RG-101 in Healthy Volunteers in Phase I Study
PR Newswire - Wed Mar 05, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122"
in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study is to evaluate safety and tolerability of RG-101 and the secondary objectives are to evaluate pharmacokinetics, viral load reduction and any impact an oral direct-acting antiviral may have on the pharmacokinetics of RG-101. Regulus Provides Strategic Update and Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights
PR Newswire - Thu Feb 27, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights.
Regulus to Present at Cowen and Company 34th Annual Healthcare Conference
PR Newswire - Wed Feb 26, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:40 am EST. The conference is being held at the Boston Marriott Copley Place.
UMB Health IT Start-up Advanced Metrics Caps Quick Entrance into Commercialization with Move to University of Maryland BioPark
PR Newswire - Wed Feb 26, 7:30AM CST
The University of Maryland (UM) BioPark and UM Ventures announced today that Advanced Metrics, a successful early-stage UM, Baltimore (UMB) startup has moved from offices on the University's campus to the BioPark. Advanced Metrics is leveraging software development and data expertise to provide solutions for the healthcare industry. It has moved quickly into commercialization since establishment only a year ago. Two employees will develop the company's technologies at the BioPark. The company also has additional staff in Mountville, Pennsylvania.
Pipeline Progress at Regulus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:20PM CST
RG-012 will be moved into clinical development next year.
Regulus Announces Timing for Fourth Quarter and Year-End 2013 Financial Results Webcast and Conference Call
PR Newswire - Thu Feb 20, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close.
Regulus Advances Orphan Disease Portfolio with Nomination of RG-012 as Clinical Development Candidate for the Treatment of Alport Syndrome
PR Newswire - Wed Feb 19, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical development, RG-012, an anti-miR targeting microRNA-21 ("miR-21"
for the treatment of Alport Syndrome, a life-threatening, genetic kidney disease with no approved therapy. Crude Oil Refining Industry in Middle East and Africa: Market Data and Business Intelligence of All Operational and New Build Refineries
PR Newswire - Thu Feb 13, 1:14PM CST
Reportbuyer.com just published a new market research report:
Regulus Appoints Head of Regulus microMarkers(TM) R&D Division
PR Newswire - Thu Feb 13, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Martin Beaulieu, Ph.D. as the head of Regulus microMarkers(TM), a research and development division of Regulus designed to support the expansion of its innovative biomarkers platform aimed at identifying microRNAs as biomarkers for disease. Regulus microMarkers(TM) utilizes a clinically-validated, highly reproducible, proprietary technology platform to extract, profile, and analyze microRNAs as potential biomarkers for disease and Regulus controls key intellectual property and know-how related to the division.
Annai Systems Names David Szekeres to its Board of Directors
PRWeb - Tue Feb 11, 5:45AM CST
Annai Systems Inc., a genomic data management solution provider, today announced that David Szekeres has joined the company's Board of Directors.
Regulus Renews Strategic Alliance with Sanofi to Focus on Orphan Disease and Oncology Targets and Receives Additional $10 Million Equity Investment
PR Newswire - Wed Feb 05, 7:00AM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS) announced today that it has renewed its strategic alliance with Sanofi to discover, develop, and commercialize microRNA therapeutics to focus on specific orphan disease and oncology targets. Regulus will lead development of its fibrosis program targeting microRNA-21 ("miR-21"
for the treatment of Alport Syndrome, an orphan, life-threatening genetic kidney disease with no approved therapy, and for its microRNA-21 ("miR-21" program in oncology. Sanofi has retained its interest in these microRNA-21 programs and has gained rights to Regulus' preclinical program targeting microRNA-221/microRNA-222 ("miR-221/222" . Regulus is responsible for advancing the clinical candidates in these programs to proof-of-concept. Sanofi shall have the exclusive option, exercisable after proof-of-concept, to take over further development and commercialization of each microRNA therapeutic program. At this stage, Regulus will have the option to co-promote any microRNA therapeutic product in the United States. 
